The author of this article talks about a P/E ratio of 20. A growing company like Celldex with 9+ drug prospects deserves a higher P/E ratio. $17 could come as soon as tomorrow.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody-focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
During the past six months, Celldex shares have rallied by more than 125%. Most of this run can be attributed to the hype surrounding CDX-011, a drug candidate that is a potential breakthrough treatment for breast cancer. CDX-011 is an antibody drug conjugate that was licensed from Seattle Genetics, Inc. (NASDAQ:SGEN). The antibody conjugate works by connecting with cancer cells that contain a protein called glycoprotein NMB (GPNMB for short). GPNMB has been shown to express itself in some of the most aggressive forms of breast cancer. Once the antibody is connected to the protein, CDX-011 releases a toxic chemotherapy payload.
In December of last year, Celldex released extremely promising data from a mid-stage trial of CDX-011. Celldex announced that the trial had demonstrated delayed tumor growth and had prolonged survival in patients with advanced and aggressive forms of breast cancer when compared to those only using the standard chemotherapy. Patients treated with CDX-011 had a median survival rate of 12.5 months compared to just 5.4 months for patients in the control arm.
Analysts are expecting potential sales of $300 million if the drug is approved. On that amount of revenue, Celldex could generate $1.60 per share. A conservative P/E ratio of 20 would yield a share price of $32.00.